Reloxin is up for review by the FDA signaling that a new botulinum-toxin product may soon be available. Currently, Allergan has 100% market share of the botulinum-toxin cosmetic market with BOTOX. With FDA approval, Medicis will soon join this market with Reloxin, which is already being used in 23 countries.

Medicis is already in the aesthetic market with their hyaluronic acid dermal filler, Restylane. Release of Reloxin would allow for further growth in the aesthetic cosmetic industry. If Reloxin is approved by the FDA, it could possibly be available for use in early 2009. To read more about Reloxin and Medicis, click on the link below.

Many medical professionals will find the opperations of a med spa compared to a regular physician's pracitce completely different. To have a successful med spa, the business plan is almost as important as the aesthetic procedures themselves. To be successful, the med spa must be built on a firm foundation including the creation of a plan, development of the concept and branding, planning services, hiring a staff, training, developing a marketing strategy as well as promotions and then executing these strategies The link below is to an article featured in Dermatology Times that looks at each of these areas in more detail, and gives an understanding of the business side of the med spa.

Each month we offer a seminar special at various locations around the country exclusively for our newsletter recipients. Our special this month is our Mesotherapy/Lipodissolve seminar in Indianapolis.

The seminar will be held on June 22, 2008, at a discounted price of $995.00 for those that enroll prior to June 19, 2008. To take advantage of this discount, please contact us at (512) 301-2125.